But the bigger problem may be finding the tests at all. Why haven’t we seen them in the drug stores? The answer is that the FDA is holding developers of these tests, like E25Bio, to the same high sensitivity standards as those required for molecular grade diagnostics. Without being granted an EUA, the companies are not manufacturing the tests. Mina and others argue that a paradigm shift is needed, so that rapid antigen tests are recognized as a “public health tool," which when combined with frequent use, will identify infectious individuals.